Elsevier unveiled PharmaPendium: a drug development decision-making platform

The new drug research initiative provides preclinical and clinical data that enable researchers to make informed decisions regarding drug enhancement

The global company in information and data analytics, Elsevier launched a platform, PharmaPendium for drug candidates.

It is an effective tool that provides data including complete Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval packages for drug development.

The platform is supported by the FDA, the Medical Devices Agency (PMDA) and the top 20 global pharma companies.

Olivier Barberan, Director of Translational Medicine Solutions spoke about how “improved access to highly relevant data plus predictive tools enhances regulatory success, safeguarding the massive investments of pharma companies.”

“Translation of preclinical research findings to humans in an efficient but safe way is one of the greatest challenges facing drug developers. We designed the new PharmaPendium to solve this,” he added.

“The platform leverages Elsevier’s expertise in curating scientific data and presents it in an intuitive and meaningful way for pharma professionals.”

PharmaPendium enables pharmaceutical professionals to prioritize safety and develop effective strategies for regulatory submissions.

It also offers advanced predictive tools such as the Drug-Drug Interaction Risk Calculator (DDIRC) and the Safety Margin Tool.

Moreover, they assist in optimising nonclinical studies and reducing the need for animal testing.

It helps to overcome various challenges from enhanced visualisation tools to intelligent autocomplete which increases discoverability and identifies important concepts.

The platform also offers an enhanced search interface for quick access to critical data, including drug metabolism and pharmacokinetics (DMPK), and chemistry information extracted from leading sources like complete FDA and EMA approval packages and FDA advisory committee documents.